| Hans-Günter Meyer-Thompson | Fachveröffentlichungen
Study Finds No Clear First-Line Treatment for Opioid Use Disorder
Study Finds No Clear First-Line Treatment for Opioid Use Disorder
Data support the removal of “first-line” terminology from British Columbia’s (BC’s) 2023 guideline update on the treatment for opioid use disorder (OUD). Clinicians and patients should engage in shared decision-making, according to the researchers.
The net health gains associated with buprenorphine/naloxone (BNX), namely reduced mortality risk, are outweighed by lower treatment retention compared with methadone, according to a decision analytic model analysis. (Medscape News Canada, Kanada, 12.01.2026)